Chondroitin sulfate nanoparticles based on co-delivery dual drug induced ferroptosis in lung cancer cells by disrupting mitochondrial oxidative homeostasis
Source abstract
Abstract
Mitochondrial REDOX homeostasis is unbalanced by large amounts of reactive oxygen species production and reduced glutathione, leading to lipid oxidation-induced ferroptosis, which enhanced cancer immunotherapy. Thus, disrupting mitochondrial redox homeostasis represents a promising strategy for the treatment of lung cancer. In this study, a co-delivery system of based on chondroitin sulfate (CS) (CS-CA-CUR-TPP, CCCT) for natural medicines (Curcumin, CUR; and Cinnamaldehyde CA) was successfully constructed, which resulted in elevated ROS levels in cancer cells. Under the action of CS specifically targeting tumor cells, CCCT NPs is enriched and taken up by lung cancer cells. Acid responsiveness causes the CCCT NPs to break and escape from the lysosome, and CUR targets and destroys mitochondria under the action of mitochondrial target head triphenylphosphine (TPP). CA collaborates with CUR to produce large amounts of ROS and reduce GSH in a time-dependent manner in mitochondria for disruption of REDOX homeostasis, and triggers ferroptosis by reducing the expression of GXP4 and xCT proteins. The immunogenic cell death (ICD) after ferroptosis promotes interferon γ (IFN-γ), TNF-a, and IL-6 secretion. Our results desmontrat CCCT can promote inhibition of tumor growth by enhancing tumor immunogenicity. This study may provide a potential avenue for the advancement of self-delivery nanoparticles to overcome resistance to apoptosis in tumor therapy. • The dual-drug delivery nanoparticles (CCCT) based on chondroitin sulfate not only inhibit the proliferation of lung cancer cells, but also have high biosafe. • The combination of CA and CUR derived from Traditional Chinese Medicine can synergistically inhibit tumor cells proliferation, thereby addressing the issue of limited efficacy observed with individual administration. • By disrupting REDOX homeostasis, CCCT NPs induce lipid oxidation, promotes ferroptosis, enhance cancer immunotherapy, and overcome apoptosis tolerance. The results further elucidate the time - and dose-dependent effect of CCCT on lung cancer by acting on mitochondria rather than cytoplasm. • The integration of stepwise targeting and dual-response technology makes CCCT NPs smarter and improves their potential for tumor treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ferroptosis and cancer prognosis · Cancer, Lipids, and Metabolism · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Jayaprasad · Int. J. Biol. Macromol. · 2024 · 264
2. Jablonska-Trypuc · Nutrients · 2018 · 1010.3390/nu10010044 ↗
3. Aghazadeh · Apoptosis · 2016 · 21 · 130210.1007/s10495-016-1288-4 ↗
4. Savage · BMC Cancer · 2016 · 16 · 90610.1186/s12885-016-2956-z ↗
5. Raz · Cell Death Dis. · 2014 · 5 · e106710.1038/cddis.2014.39 ↗
6. Yan · Acta Biomater. · 2024 · 188 · 32910.1016/j.actbio.2024.09.015 ↗
7. Tang · Cancer drug resistance · 2024 · 7 · 41
8. Bai · Cell Death Dis. · 2024 · 15 · 81910.1038/s41419-024-07209-0 ↗
9. Won · Eur. J. Pharmacol. · 2024
10. Liu · J. Inflamm. Res. · 2024 · 17 · 847110.2147/JIR.S493001 ↗
11. Xie · ACS Nano · 2024 · 18 · 3243810.1021/acsnano.4c04741 ↗
12. Tang · Thorac Cancer · 2021 · 12 · 121910.1111/1759-7714.13904 ↗
13. Chen · Oxid. Med. Cell. Longev. · 2023 · 2023
14. Shi · Adv Healthc Mater · 2024 · 1310.1002/adhm.202303837 ↗
15. Meng · Oncotarget · 2017 · 810.18632/oncotarget.20059 ↗
16. Wang · J Nanobiotechnology · 2021 · 19 · 15210.1186/s12951-021-00895-4 ↗
17. Cai · Biomacromolecules · 2017 · 18 · 167710.1021/acs.biomac.7b00424 ↗
18. Li · Carbohydr. Polym. · 2021 · 255
19. Shi · Carbohydr. Polym. · 2021 · 254
20. Huang · J. Med. Chem. · 2022 · 65 · 995510.1021/acs.jmedchem.2c00640 ↗
21. Zielonka · Chemical reviews · 2017 · 11710.1021/acs.chemrev.7b00042 ↗
22. Kalyanaraman · FASEB J. : official publication of the Federation of American Societies for Experimental Biology · 2022 · 3610.1096/fj.202101862R ↗
23. Wang · J Nanobiotechnology · 2020 · 18 · 810.1186/s12951-019-0562-3 ↗
24. Zheng · J Control Release · 2021 · 336 · 15910.1016/j.jconrel.2021.06.021 ↗
25. Zhou · Acta Pharm. Sin. B · 2023 · 13 · 315310.1016/j.apsb.2022.11.024 ↗
26. Huang · Eur J Pharm Sci · 2024 · 204
27. Jiang · Small · 2020 · 16
28. Hadji · J Control Release · 2022 · 342 · 9310.1016/j.jconrel.2021.12.032 ↗
29. Fang · Adv Healthc Mater · 2023 · 12
30. Yi · Pharmaceutics · 2022 · 1410.3390/pharmaceutics14081534 ↗
31. Guo · Int J Pharm · 2024 · 66610.1016/j.ijpharm.2024.124744 ↗
32. Deng · J Control Release · 2024 · 366 · 68410.1016/j.jconrel.2024.01.024 ↗
33. Huang · Eur. J. Med. Chem. · 2024 · 265
34. Barnwal · Acs Biomater Sci Eng · 2023 · 9 · 640910.1021/acsbiomaterials.3c00469 ↗
35. Zhang · J Immunother Cancer · 2023 · 1110.1136/jitc-2023-006785 ↗
36. Zhang · Phytother Res. · 2024 · 38 · 204110.1002/ptr.8149 ↗
37. Fanale · BMC Cancer · 2023 · 23 · 43710.1186/s12885-023-10911-5 ↗
38. Liu · Adv Mater · 2024 · 36